High-throughput QIAxcel[®] based subtyping: Enhanced epidemiologic surveillance of Campylobacter jejuni

Eduardo Taboada¹, Steven Mutschall¹, and Mirjana Kozulic²

¹ Campylobacter Genomics Laboratory, Division of Science and Technology, Laboratory for Foodborne Zoonoses, Public Health Agency of Canada, Lethbridge, Canada ² QIAGEN Instruments AG, Garstligweg 8, CH-8634 Hombrechtikon, Switzerland

C. jejuni – a significant public health concern


- C. jejuni is the leading cause of foodborne bacterial enteritis in Canada and worldwide.
- Approximately 90% of human foodborne infections are caused by C. jejuni.
- Campylobacteriosis causes symptoms such as fever, abdominal pain, nausea, vomiting, and diarrhea.
- In Canada, there are probably ~300,000 cases a year, costing in total ~\$300 million.

Challenges in C. jejuni subtyping

- Pulsed-field gel electrophoresis (PFGE) is a gold standard method for many bacterial foodborne pathogens, but not optimal for C. jejuni due to fingerprint "instability" (Barton et al., 2006).
- **flaA typing** through RFLP or sequencing of flaA alleles is rapid and inexpensive. However, high rates of recombination in C. jejuni can lead to erroneous genotypic clusters.
- Multi locus sequence typing (MLST) is a gold standard for C. jejuni subtyping and has several advantages such as unambiguous and highly portable sequence data. However, MLST is a low-throughput method lacks resolution in some epidemiological contexts, and is costly to implement.

Comparative genomic fingerprinting (CGF)


- Pan-genome = core genes + accessory genes of a species
- Accessory genes are responsible for many 'major phenotypic traits' of importance
- The accessory genome houses most of the genetic variability. Its diversity can be utilized for strain subtyping. The 'true' gold standard is the whole-genome phylogeny and a good subtyping method should compare favorably to the whole-genome phylogeny.



The pan-genome concept

QIAxcel Advanced improves CGF data analysis and workflow

Improved accuracy of CGF band sizing analysis: fewer falsely detected or misclassified bands.




As opposed to the standard gel electrophoresis, the QIAxcel platform enables automated streamlined analysis of CGF mPCRs, thereby facilitating high-throughput analysis and improving the discriminatory power.

Advantages:

- Automated analysis
- Automated data reporting
- Decreased time for sample-answer (~48 isolates per work day)
- Reduced costs (~\$7 USD per isolate)

CGF workflow



CGF workflow timeline. Complete CGF fingerprint analysis of 12 isolates in less than 5 hours, with minimal hands-on time



Public Health Agency of Canada


Agence de la santé publique du Canada


Accessory genome

Group-specific aene



- The method is based on presence/absence of accessory genes.
- Each marker has intermediate carriage in the *C. jejuni* population = 'random' binary marker.
- Multi-marker profile: 40 markers $\rightarrow 2^{40}$ possible fingerprints.
- SNP-free PCR primer design \rightarrow multiplex PCR \rightarrow 8 x multiplex PCRs = a comparative genomic fingerprint.





Conclusion

- There are a number of challenges with existing methods of subtyping *Campylobacter jejuni*.
- CGF exploits significant differences in accessory genome content in *C. jejuni* and thereby has a greater discriminatory power than MLST.
- Adoption of the QIAxcel Advanced System has improved CGF data analysis and facilitated method assessment/ deployment, resulting in:
- Improved sensitivity and accuracy
- A simplified, automated workflow
- Automated data reporting
- Increased throughput.
- A common method for subtyping has made it feasible to envision national networks for campylobacter surveillance, involving medical research and environmental settings, as well as the food production and agricultural industries.
- Comprehensive human, farm-to-fork, and source-to-tap surveillance (under a national database), will lead to: Improved understanding of campylobacter epidemiology
- The development and assessment of intervention strategies to mitigate risk.

The applications presented here are for molecular biology applications. They are not intended for the diagnosis, prevention or treatment of a disease

For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit handbook or user manual. QIAGEN kit handbooks and user manuals are available at <u>www.qiagen.com</u> or can be requested from QIAGEN Technical Services or your local distributor.

Trademarks: QIAGEN®, QIAxcel® (QIAGEN Group). Registered names, trademarks, etc. used in this document, even when not specifically marked as such, are not to be considered unprotected by law. © 2014 QIAGEN, all rights reserved

Sample & Assay Technologies